Cankure (Capsules)

An ideal functional food supplement during cancer therapy

Curcumin, the natural orange yellow pigment in the spice turmeric is attributed for various miraculous medicinal applications of turmeric world over. Notably, S E Asia where turmeric is widely used as food ingredient and cosmetic has very low incidence of cancers especially colon and skin.

In various animal studies, Curcumin was found to inhibit progression of chemically induced cancers in colon, breast, prostate, and skin. Curcumin kills cancer cells by inducing apoptosis (programmed cell death). Curcumin inhibits new blood vessel formation that is vital for growth and spread of cancer, by interfering with various enzymes, receptors and growth factors. Curcumin inhibits P - glycoprotein and thus may reverse drug resistance of chemotherapy in cancers.
The US National Institute of Health has four clinical trials registered that are recruiting patients to test Curcumin for Pancreatic cancer, Multiple myeloma, Alzheimer’s and Colorectal cancer.
Lactobacillus, another ingredient in CANKURE belongs to Probiotics. The possible health benefits of Probiotics are:

  1. Prevention of cancer and tumor growth
  2. Improving intestinal tract health
  3. Enhancement of the immune system
  4. Enhancing the bioavailability of nutrients

In a study, Lactic acid bacteria (a type of probiotic bacteria) inhibited colon cancer in humans, probably through various mechanisms like alteration of metabolic activity of intestinal micro flora, alternation of physiochemical conditions in the colon, enhancing the host’s immune response etc.






Each Hard Gelatine Capsule Contains:
Curcumin (extracted from Curcuma longa)       350 mg
Lactobacillus acidophilus                               100 mg

Indication As functional food supplement in cancer.
Dosage Two capsules twice daily preferably after food

In a reference Curcumin demonstrated no toxicity up to 8,000 mg/day in humans when taken by mouth for 3 months (in of patients etc), in another reference Curcumin has showed no toxicity when administered at doses of 1-8 g/day and 10 g/day in humans.

Caution Please consult your physician before usage of Cankure, if you are suffering from active peptic ulcer, G I bleeding and bile duct obstruction.
Packing 60 Capsules in one HDPE Container.
*Disclaimer These statements have not been evaluated by the US Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease

References :


  1. Turmeric may ward off many diseases: US Scientists: Business line, Financial Daily from THE HINDU group of publications, Wednesday, August 31, 2005

  2. Zhou S et al (2004): Herbal modulation of P-glycoprotein. Drug Metab Rev 36 (1); 57-     104.

  3. Marjan J van Erk et al (2004): Time- and dose-dependent effects of Curcumin on gene expression in human colon cancer cells, Journal of Carcinogenesis, 3:8.

  4. Jo Shim et al (2003): Irreversible inhibition of CD13 / aminopeptidase N by the antiangiogenic agent Curcumin. Chemistry and Biology 10(8): 695-704.

  5. Perking S et al (2002): Chemopreventive efficacy and pharmocokinetics of Curcumin in the Min/+ mouse, a model of familial Adenomatus polyposis. Cancer Epidem Biomarker Preview 11(6); 535-540.

  6. Hour T C et al (2002): Curcumin enhances cytotoxicity of chemotherapeutic agents in Prostate cancer cells by inducing p21 (WAF1 / C1P1) and C/EBP beta expressions and suppressing NF-Kappa B activation. Prostate 51 (3); 211-8.

  7. Afaq F et al (2002): Botanical antioxidants for chemoprevention of carcinogenesis. Plant Biosc 7; 784-92.

  8. Hao Z M et al (2002): Curcumin exerts multiple suppressive effects on human breast carcinoma cells. Int J Cancer 98 (2); 234-240.

  9. Iano H & Onoda M (2002): Prevention of radiation-induced mammary tumors. Int J Radiat Onco Biol Phys 52 (1); 212-223.

  10. Jaga K & Duvvi H (2001): Risk reduction for DDT toxicity and carcinogenesis through dietary modification. J R Soc Health 121 (2); 107-113.

  11. Cheng A I et al (2001): Phase I Clinical trial of Curcumin, a chemopreventive agent, in patients with high-risk oral premalignant lesion.  Anticancer Res 21(4B); 2895-900.

  12. Plummer SM et al (2001): Clinical development of Leukocyte cylooxygenase actitivity as a systemic biomarker for Cancer chemopreventive agents. Cancer Epidem Biomarkers Preview 10 (12); 1295-1299.

  13. Sharma R.A et al (2001): Pharmacodynamic and pharmacokinetic study of oral Curcuma exrtract, in patients with colorectal cancer. Clin Canc Res 7 (7); 1894 – 1900.

  14. Bush J.A et al (2001): Curcumin induces apoptosis in Human melanoma cells through a Fas receptor / Caspase  8 pathway independent of P53.  Exp cell res 271  (2); 305-311.

  15. Ikezaki S et at (2001): Chemopreventive effects of Curcumin on Glandular Stomach      carcinogenesis induced by N-methyl-N'-nitrosoguanidine and Sodium chloride in rats. Anticancer res 21 (5); 3407 -11.

  16. A. Goel, C. Boland & D.Chauhan (2001): Specific inhibition of cylooxygenase -2 (COX-2) expression by dietary Curcumin in HT- Human colon cancer cells. Cancer Letters 172: 111-118.

  17. Phan TT et al (2001): Protective effects of Curcumin against oxidative damage on skin cells in-vitro, its implication for wound healing. J Trauma 51 (5); 927-31.

  18. Sharma et al (2000): Spice extracts on dose-modifying factors in radiation inactivation of bacteria. J Agri Food Chem 48; 1340-44.

  19. Dorai et al (2000): Therapeutic potential of Curcumin in human prostate cancer. Curcumin induces apoptosis in both androgen - dependent and androgen – independent prostate cancer cells. Prostrate Cancer and Prostatic diseases; 3, 8493.

  20. Pasqualini R. et al (2000): Aminopeptidase N Is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res, 602:722-727.

  21. Curcumin antioxidant and anti-inflammatory and inhibited chemically induced carcinogenesis in skin, fore stomach and colon. It induced apoptosis and inhibited tumor growth in colon (1999). Cancer res 59 (3); 597-601.

  22. Surh Y (1999): Molecular mechanism of chemopreventive effects of selected dietary and medicinal phenolic substances. Mutat Res 428 (1-2); 305-27.

  23. Kawamori T (1999): Chemopreventive effect of Curcumin, a naturally occurring anti – inflammatory agent, during the promotion/progression stages of colon cancer. Cancer  Res 59(3); 597-601.

  24. Goel A et al (1999): Inhibition of cyclooxigenase-2 expression by dietary Curcumin in HT-29 human  colon cancer cells. Proceeding of the American Association for Cancer Research (AACR) Annual meeting 40; 528-9.

  25. Oyama Y et al (1998): Protective actions of 5- n  Alkylated Curcumin on living cells suffering from oxidative stress. Euro J Pharmacol 360(1); 65071.

  26. Roth G N et al (1998): Novel bioactivities of Curcuma longa constituents. J of Nat Prod 61; 542-545.

  27. Verma SP et al. (1998). The inhibition of the estrogenic  effects of pesticides and environmental chemicals by Curcumin and isoflavonoids. Environ Health Perspect 106:807-12.

  28. Sikora E et al (1997): Inhibition of proliferation and apoptosis of human and rat T lymphocytes by  Curcumin, a curry pigment. Biochem Pharmacol 54(8); 899-907.

  29. Kelloff G J et al (1996): NCI, DCPC Clinical development plan, Curcumin. J Cell Biochem Suppl 26 S; 72-85.

  30. Commandeur JNM et al (1996): Cytotoxicity and cytoprotective activities of natural compounds, the case of Curcumin. Xenobiotica 26(7), 667-680.

  31. Goud V.K, Krishnaswamy K (1993): Mechanism of anti-carcinogenesis of Curcumin and Turmeric, Symposium on therapeutic potential of Turmeric and Curcumin. National Institute of Nutrition (N I N), Hyderabad, India.

  32. Effect of oral Curcumin administration on Serum peroxides and cholesterol levels in human volunteers (1992). Indian J Physio Pharmacol 64 (5); 273 5.

  33. Ammon H P T & Wahl M A (1991): Pharmacology of Curcuma longa. Planta Med 57; 1-7.

  34. Polasa K, Sesikeran B & Krishnaswamy K (1990): Antimutagenisity of Curcumin and Turmeric. Proceedings of the Nutritional Soc of Ind; 36, 102.

  35. Masuda T et al (1988): Synthesis of +/-- Casscumunin A and B, new curcuminoid antioxidants having protective activity of the living cell against oxidative damage. J of Nat Prod 61(5); 609-13.

  36. Srimal R C (1987): Curcumin. Drugs of the future 12 (4); 331  333.

  37. Mehta K et al: Antiproliferative effect of Curcumin against human breast tumor cell lines. Anticancer drugs 8(5); 470-81.

  38. Antihepatotoxic principles of Curcuma longa rhizomes. Kiso Y et al (1983): Planta Med 49;185–187

  39. Dhar et al (1968): Screening of Indian plants for biological activity. Part - I, Indian J of Expt Biology 6; 232.


  40. Pamela Manson: Dietary Supplements (2001): Pharmaceutical Press, London

  41. Rolfe RD. The role of probiotic cultures in the control of gastrointestinal health. J Nutr 2000; 130: 396S-402S.

  42. Rao CV et al. Prevention of colonic preneoplastic lesions by the probiotic Lactobacillus acidophilus NCFMTM in F344 rats. Int J Oncol. 1999 May; 14(5):   939 – 44.

  43. Collins MD et al. Probiotics, prebiotics and synbiotics: approaches for modulating the microbial ecology of the gut. Am J Clin Nutr 1999; 69: 1052S-1057S.

  44. Canganella F et al. A microbiology investigation on probiotic pharmaceutical products used for human health. Microbiol res 1997; 152: 171-179.

  45. Mital BK, Garg SK. Anticancerogenic, hypocholesterolemic and antagonostic activities of Lactobacillus acidophilus. Crit Rev Microbiol 1995; 21:175-214.

  46. Fuller R ed. Probiotics: The Scientific basis. London, Chapman & Hall, 1992.

  47. Fuller R. A review: Probiotics in man and animals. J Appl Bacteriol 1989:66:365-378.
top              back to formulations